- Home
- BIIB vs FNF Comparison
BIIB vs FNF Comparison
Compare BIIB & FNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FNF
- Stock Information
- Founded
- BIIB 1978
- FNF 1847
- Country
- BIIB United States
- FNF United States
- Employees
- BIIB N/A
- FNF N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FNF Specialty Insurers
- Sector
- BIIB Health Care
- FNF Finance
- Exchange
- BIIB Nasdaq
- FNF Nasdaq
- Market Cap
- BIIB 18.7B
- FNF 15.2B
- IPO Year
- BIIB 1991
- FNF N/A
- Fundamental
- Price
- BIIB $157.08
- FNF $54.89
- Analyst Decision
- BIIB Buy
- FNF Strong Buy
- Analyst Count
- BIIB 24
- FNF 5
- Target Price
- BIIB $174.62
- FNF $71.00
- AVG Volume (30 Days)
- BIIB 1.6M
- FNF 1.0M
- Earning Date
- BIIB 10-30-2025
- FNF 11-06-2025
- Dividend Yield
- BIIB N/A
- FNF 3.67%
- EPS Growth
- BIIB N/A
- FNF 16.93
- EPS
- BIIB 10.97
- FNF 3.93
- Revenue
- BIIB $10,065,900,000.00
- FNF $13,634,000,000.00
- Revenue This Year
- BIIB $2.97
- FNF $1.23
- Revenue Next Year
- BIIB N/A
- FNF $10.97
- P/E Ratio
- BIIB $14.28
- FNF $13.88
- Revenue Growth
- BIIB 4.77
- FNF 7.26
- 52 Week Low
- BIIB $110.04
- FNF $50.61
- 52 Week High
- BIIB $179.20
- FNF $66.72
- Technical
- Relative Strength Index (RSI)
- BIIB 64.92
- FNF 38.91
- Support Level
- BIIB $148.90
- FNF $54.35
- Resistance Level
- BIIB $155.33
- FNF $56.08
- Average True Range (ATR)
- BIIB 4.79
- FNF 0.91
- MACD
- BIIB 0.47
- FNF -0.00
- Stochastic Oscillator
- BIIB 96.41
- FNF 17.16
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FNF FNF Group of Fidelity National Financial Inc.
Fidelity National Financial Inc is a provider of (i) title insurance, escrow and other title-related services, including trust activities, trustee sales guarantees, recordings and reconveyances and home warranty and (ii) transaction services to the real estate and mortgage industries. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. Substantially all of the company's revenue is generated in the United States.